Greenphire announced that it has formed an exclusive strategic partnership with the clinical trials division of Merge Healthcarea provider of clinical trial solutions, to offer integrated function between Merge’s EDC technology and Greenphire’s eClinicalGPS site and vendor payment management technology. The integrated EDC and payment technology offering will enable both companies' pharmaceutical, medical device, and CRO clients to further automate and centrally track all clinical payments on a global basis.
“Our alliance with Merge enables us to collaboratively bring an innovative and complementary set of technologies to the clinical research industry, driving additional efficiency to sponsors, CROs and sites on a global basis,” said Greenphire CEO Sam Whitaker. “Our integrated functionality with Merge adds value to existing Merge and Greenphire clients, and offers operational efficiencies which our industry has never achieved previously."
The functionality achieved through this strategic partnership will streamline implementation processes and create additional efficiencies for clients, enabling users to automate research site and clinical vendor payments in local currency through Greenphire's centralized, global web-based payment engine. It will also streamline setup times, decrease sponsor, site and CRO administrative burdens on an on-going basis, reduce payment administration costs and timelines, and increase site satisfaction. Additionally, centrally automating global clinical payments will significantly reduce costs for both sponsors and CROs by electronically automating what have historically been multi-step and manual payment administration processes.
A Greenphire spokesperson added that Merge was a great fit for Greenphire as it is established company with the resources to efficiently manage the technology integration, as well as a top EDC provider with a good existing client base. The Merge pertnership extends Greenphire's payment capabilities across a whole suite of established clinical technologies. The company's previous integration partnerships are with Almac for IVRS/IWRS and Bio-Optronics for CTMS.
“This partnership demonstrates that Merge is committed to addressing the needs of our clinical trials customers, specifically those who have asked for an integrated site payment system for their clinical programs,” said Jeff Surges, CEO of Merge Healthcare. “We’re looking forward to working with Greenphire and to improving workflow processes and efficiencies for our clients.” To date, Merge is already using the integrated functionality to execute three unique projects, with several more planned for 2012.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.